A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin

• Status: Completed
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to assess the effect of LEO 130852A gel 1% in maintaining skin thickness in healthy skin treated with steroid.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: LEO Pharma
• Treatments: Clobetasol

Criteria

Inclusion Criteria:

• Healthy male volunteers, 25 to 50 years old inclusive

• Healthy skin on volar arms with a hairless area sufficient for measurements

Exclusion Criteria:

• Clinical skin atrophy, telangiectasia or striae on volar arms

• Presence of any skin condition or colouration that would interfere with test sites or the response or assessment

• Fitzpatrick skin type IV - VI

• History or current evidence of infection, eczema or other relevant skin disease